SNOA
Sonoma Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
7.16 / 10
Outperform
Liquidity flow evaluation stands at 7.16/10, reflecting robust fund inflows with a positive small-cap trend (0.5008). However, block, medium, large, and extra-large flows are negative, indicating institutional hesitation. There are no analyst ratings available (ana_eval = -1). The mixed flow signals—optimistic at the small scale but pessimistic at larger scales—suggest that while retail interest persists, larger investors remain cautious, reinforcing the overall neutral-to-negative outlook.
Fund Flow Rating
What is the analyst consensus for SNOA?
- SNOA holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.16/10 (Outperform).
